Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months)

Related Keywords

Chicago ,Illinois ,United States ,Sweden ,Hall On ,Orebro ,American ,Jean Luc Van Laethem ,Sumeet Ambarkhane ,Peter Ellmark ,Frank Hoerning Andersen ,Aptevo Therapeutics Inc ,Orion Corporation ,American Society Of Clinical Oncology ,Cohesion Bureau ,Market Research ,Biotheus Inc ,Shanghai Henlius Biotech Inc ,Alligator Bioscience ,Clinical Oncology ,Annual Meeting ,Objective Response Rate ,Response Evaluation Criteria ,Solid Tumors ,Overall Survival ,Gastrointestinal Cancer Gastroesophageal ,Shanghai Henlius Biotech ,Nasdaq Stockholm ,Present Positive Phase ,Pancreatic Cancer ,Ihr Portfolio ,